Dr. Allen W. Davidoff, phd
Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven phase II studies, and one NDA. Prior to forming XORTX, Allen was the Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (seven years) ( Trillium TRIL:NASDAQ) and Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp.
James Fairbairn, cpa, icd.d
James Fairbairn has 20+ years in senior finance roles with emerging companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim holds a Bachelor of Arts from the University of Western Ontario. He is a director of several junior listed companies.
Brian Mangal, msc
BioStatistics, Director Business Development, Product Development
Brian Mangal (12 years of clinical development experience) was the former Director of Biostatistics, Cardiome Pharma Corp. where he was responsible for all biometric activities related to the advancement of Cardiome’s clinical programs. Brian’s clinical development experience includes design, analysis and reporting on over 50 clinical trials, three FDA submissions, one TPD (Therapeutic Products Directorate) submission, and a successful EMEA (European Medicines Agency) submission. Prior to Cardiome, Brian worked on building a CRO (Contract Research Organization), Everest Clinical Research, specializing in dealings with the National Institute of Health in the US and as a Biostatistician at Pharmacia/Pfizer where he worked on the successful New Drug Application (NDA) for Linezolid and numerous successful trials with Celecoxib.
Dr. Alan F. Moore, phd, founding board member
Executive Consultant: Clinical and Regulatory Affairs
Dr. Alan Moore has extensive clinical development experience and 23 years of senior management experience in pharmaceutical R&D including most recently as CEO of BetaStem inc. During his esteemed career, he has completed 11 IND (investigational new drug) applications or supplemental IND’s, 15 phase I studies, 12 phase II studies, seven phase III studies and two new drug applications.